Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective by Zeidler, Jan et al.
Zeidler et al. Health Economics Review 2012, 2:20
http://www.healtheconomicsreview.com/content/2/1/20RESEARCH Open AccessBiologic TNF inhibiting agents for treatment of
inflammatory rheumatic diseases: dosing patterns
and related costs in Switzerland from a payers
perspective
Jan Zeidler1*, Thomas Mittendorf2, Rüdiger Müller3 and Johannes von Kempis3Abstract
Background: To obtain detailed real-life data on costs and dosing patterns in the utilisation of the TNF inhibitors
adalimumab, etanercept, and infliximab in patients treated in Switzerland.
Methods: Administrative claims processed by a major Swiss health insurer between 2005 and 2008 were analysed.
Patients with inflammatory rheumatic diseases (IRDs) with at least one prescription for adalimumab, etanercept, or
infliximab were identified. All-cause and disease-specific costs, as well as daily costs of treatment, were calculated.
Dosing patterns and discontinuation rates were analysed.
Results: A total of 555 IRD patients were identified. All-cause costs during the 12 months after the index event
were 20,555CHF in the etanercept group, 24,152CHF in the adalimumab group, and 27,614CHF in the infliximab
group. The most important cost driver was mean TNF inhibitor drug cost, which was 15,613CHF in the etanercept
group, 19,166CHF in the adalimumab group, and 21,313CHF in the infliximab group. Discontinuation rates during
the first year after the index event were 46.8% in etanercept, 41.3% in adalimumab, and 51.2% in the infliximab
group. Rates of dosage increase were 13.3% in the etanercept group, 13.0% in the adalimumab group, and 14.1% in
the infliximab group. When time on treatment was considered, daily costs of treatment were similar for etanercept
and adalimumab, but were higher for infliximab.
Conclusions: Marked differences in costs between subcutaneous and intravenous therapies were observed. Among
the three groups of patients defined by TNF inhibitor treatment, costs for the infliximab group were highest during
the year after the index event.
Keywords: Inflammatory rheumatic diseases, Claims data, Cost analysis, Dosing patterns, Switzerland, Tumor
necrosis factor inhibitorBackground
Inflammatory rheumatic diseases (IRDs), such as rheuma-
toid arthritis (RA), ankylosing spondylitis (AS), and psori-
atic arthritis (PsA), are characterized by chronic
inflammation of the musculoskeletal system, especially the
joints and spine. The combination of disease-modifying
anti-rheumatic drugs (DMARDs) and the development of
tumour necrosis factor (TNF) inhibitors have for the first* Correspondence: jz@ivbl.uni-hannover.de
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in any medium, provided the original work is ptime been shown to induce the clinical remission of RA
and delay or halt the clinical and radiological progression
of the disease, thus improving the quality of life of many
patients [1]. There is also clear evidence that anti-TNF
therapy is efficacious in patients with AS and PsA. Ac-
cordingly, TNF inhibitors comprise an important part of
current treatment recommendations [2-4].
The first available TNF inhibitors were infliximab, eta-
nercept, and adalimumab. All three are approved for the
treatment of RA, AS, and PsA. Drug costs for the TNF
inhibitors used to treat IRDs are far greater than those
of conventional DMARDs. Economic considerationsn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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inhibitors as well as the placement of these drugs in the
care sequences developed by health insurance decision
makers. The real-life costs of anti-TNF treatment for RA
have been studied in the US and Spain; however, no data
are available for AS or PsA [5-10]. Between-country dif-
ferences in health care systems have resulted in a high
variance in the outcomes of health economic studies
and limit the generalisability of cost estimates from
one country to another [11,12]. Furthermore, dosage
increases in clinical practice may have significant cost
implications for patients and payers, given the linear re-
lationship between dosage and costs [5].
A study was conducted to obtain detailed real-life data
on costs and dosing patterns for the TNF-inhibiting
agents adalimumab, etanercept, and infliximab when
used to treat IRD patients in Switzerland. Using admin-
istrative claims data from a major Swiss health insurer,
we sought to estimate the all-cause and disease-specific
costs of anti-TNF-treated patients, the costs incurred in
different sectors of care (e.g. ambulatory care, medica-
tions, devices and aids), and the dosing patterns and dis-
continuation rates for TNF inhibitors.
Methods
Perspective
The study was designed from the perspective of the
largest Swiss health insurer, Helsana, which has nearly
1.9 million insurants representing one quarter of the
7.8 million inhabitants of Switzerland. All costs of the
TNF-inhibiting drugs, as well as all outpatient cost
domains, were taken into account. Co-payments and
out-of-pocket payments by patients are not relevant
from the perspective of a health insurer. Patients in
Switzerland have full coverage for most health care
services with a base deductible of 300CHF and an add-
itional co-payment of 10-20% of medication costs. The
total is capped at 700CHF per year. Patients can elect
to have a higher base deductible. However, due to the
chronic character of IRD it is most likely that almost
all of the identified patients will have selected the low-
est deductible. In our study, personal contributions
and co-payments by patients were not taken into ac-
count. Costs were calculated based on claims data that
included co-payments made by patients. Furthermore,
Switzerland has a mandatory pharmacy discount of
2.5% that is applied to drug prices, which was
deducted in the analysis.
Patients and cost domains
All patients receiving at least one prescription for adali-
mumab, etanercept, or infliximab during the years 2005-
2008 were identified from the nationwide claims data
base. Patients under the age of 18 were excluded fromanalysis. Some of the identified patients may have been
treated with a TNF inhibitor for a condition other than
an IRD (e.g., Crohn’s disease, psoriasis). Since ICD codes
were not recorded in Swiss claims data following legal
regulations, we elected to exclude patients who were
treated in two or more quarters per year by a gastro-
enterologist or dermatologist.
In addition to basic claims data, which included infor-
mation on age and gender, detailed information was
extracted on a per-patient basis for the following cost
domains: outpatient care, ambulatory care provided in
hospitals, medications, laboratory tests, devices and aids,
and other claims.
The cost domain “ambulatory care provided in hospi-
tals” included health services such as medical consulta-
tions and treatments, infusions, reports by doctors, and
ultrasonic testing and radiographs that were provided on
an outpatient basis by hospitals. Cost data for inpatient
treatment episodes were not available in the data set on
a per-patient basis. The treatment date and identity of
the specialist group of the treating physician were avail-
able for most claims.
Information from the different health care sectors was
linked via an unique identification number for each pa-
tient. Health services that could not be included expli-
citly in one of the specific cost domains were
summarised in the category “other claims”.
Cost analyses
The study was designed as a cost analysis. This type of
methodology provides information about the frequency
of use and types of different therapies, costs of therapy,
treatment patterns, and general conditions in health care
for a specific disease. Annual costs were calculated for
the year following the index event. The first anti-TNF
claim in the study period was selected as the index claim
or event. Only patients for whom data were available for
at least a full year after the index event were included in
the analysis. Patients were classified according to the
index TNF inhibitor, i.e., etanercept, adalimumab, or
infliximab. Patients who switched therapy to another
TNF inhibitor within the follow-up period were not
included in the analysis.
IRD-related versus non-IRD-related direct costs
The study aimed at discriminating IRD-related from non-
IRD-related direct costs. For the identification of IRD-
specific resource use, standardised classifications in Swiss
health care were used, including the Tarmed classification,
the pharmaceutical specialties list (Spezialitätenliste), the la-
boratory analyses list (Analyseliste), and the “Mittel- und
Gegenstände-Liste” (MiGeL). Based on these classification
systems, each individual claim was classified as IRD-related
or not-IRD-related for the analysis. To enhance the
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IRD-related only if they were provided by a rheumatologist
(i.e., more general services which could also relate to other
conditions if invoiced by a general practitioner). Therefore,
IRD-related costs were calculated only for patients who
were treated at least once by a rheumatologist during the
year after the index event.
Analysis of dosing patterns
TNF inhibitors are available in different administration
forms and dosages. Etanercept and adalimumab are
administrated subcutaneously (SC). The recommended
dosage for etanercept is 25mg twice a week or 50mg
once weekly. Adalimumab is recommended at a dosage
of 40mg every other week, but the dosage can be
increased to 40mg weekly. Infliximab is administrated
intravenously (IV) with a recommended dose of 3mg
per kg of body weight for RA and 5mg per kg for AS
and PsA. Additional infusions are administered 2 and
6 weeks after the initial infusion and at 8-week inter-
vals thereafter. In addition, the dosing can be increased
and infusion intervals shortened depending on patient
needs or other circumstances. Since the dosing of
infliximab depends on the patient´s body weight,
which was not available in the database, the dose
administered in the third infusion (i.e., associated with
the third claim) was taken to be the recommended pa-
tient dose for the analysis. For patients who had less
than three infliximab claims, the dose associated with
the first claim was taken to be the recommended dose.
The time horizon was calculated for each claim, for
which the prescription should suffice, assuming that
the treatment was initiated with the recommended
dosing scheme. Using this approach, an average annual
treatment length was calculated, i.e., the average num-
ber of days for which the filled prescriptions should
last assuming treatment based on labelling recommen-
dations. For example, a prescription of one syringe of
adalimumab was assumed to last for 14 days. The
average annual treatment length within the respective
time horizon was calculated for one, two, and three
years after the index event. For the analysis of the first
year only patients who had at least one year between
the first and last TNF inhibitor claim were taken into
account for the analysis. The same approach was used
when performing the two- and three-year analyses, i.e.
only patients who had at least two- and three-years
between first and last TNF inhibitor claim were
included.
In addition, a separate calculation of adherence pat-
terns was conducted using the methodology proposed by
Wu et al. who investigated TNF inhibitor discontinuation
rates and treatment patterns in a US setting [13]. Discon-
tinuations in treatment were defined as: For etanercept and adalimumab, a gap of more than
60 days between the end of the recommended
dosage and the following claim.
 For infliximab, discontinuation was assumed if one
of the following cases occurred:
1) the gap between the first and second infusion was
more than 14 plus 60 days,
2) the gap between the second and third infusion
was more than 28 plus 60 days,
3) the gap between subsequent infusions was more
than 56 plus 60 days.
A prescription gap was defined as the number of days
between a TNF-inhibitor prescription and the following
prescription. With the first appearance of a gap, a pa-
tient was classified as being not continuously treated. In
a third analysis step, the percentage of patients receiving
more than the recommended dosage was calculated
using the approach of Wu et al. [13]. The weekly dosage
for each prescription was calculated as:
 Quantity x 7 / prescription gap (for adalimumab)
 Dosage x Quantity x 7 / prescription gap (for
etanercept)
 Number of vials x 7 / prescription gap (for
infliximab)
The average dosage within the first year of treatment
was compared with the recommended dosage (e.g., 0.5
syringes per week for adalimumab). For infliximab, the
reference dosage was chosen to be that associated with
the third claim. An increase in dosage was defined as an
observed average weekly dosage 33.3% higher than the
recommended dosage (etanercept or adalimumab) or an
average weekly dosage 33.3% higher than the reference
dosage (infliximab). Patients with fewer than two claims
for any TNF inhibitor were excluded from the analysis.
Analysis of average daily costs of treatment
In addition to the annual costs of TNF inhibitor treat-
ment, daily costs of treatment were analysed. For each
patient, the number of days with active TNF inhibitor
treatment was calculated taking into account the recom-
mended dosage. All active treatment-related costs were
aggregated and divided by the number of days of treat-
ment in order to estimate the mean daily treatment cost.
Software, statistical analyses and data protection
Data management and statistical analyses were per-
formed using MicrosoftW Access 2007 and Excel 2007.
Additionally, SPSS version 15 was used for specific stat-
istical analyses. In general, comparisons among the anti-
TNF treatment cohorts were made using independent
Table 1 Number of patients and demographic data
Etanercept Adalimumab Infliximab
Patients 233 201 121
Mean age (standard deviation) 54 (15,20)* 51 (15,12)** 41 (12,16)
Female, % 63*** 59 51
* p < 0.05 compared with adalimumab and infliximab.
** p < 0.05 compared with infliximab.
*** p < 0.05 compared with infliximab.
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for nominal variables. Wilcoxon tests were performed to
facilitate cost comparisons among the three groups. All
tests were performed with two-tailed α = 0.05.
The data were available on a pseudonymised basis.
Pseudonymisation precluded the identification of indi-
vidual patients and de facto means anonymous data en-
suring data protection demands. Hence, current data
protection regulations were addressed with this
approach.Results
Study population
A total of 1,433 patients with at least one anti-TNF claim
between 2005 and 2008 were identified and selected. 788
of these patients were ≥18 years of age with full evaluable
data for at least one year after the first anti-TNF claim.
Of these patients, 555 were not treated in two or more
quarters by a gastroenterologist or dermatologist and
were defined as IRD patients (Figure 1).
The mean age of these patients was 50 (SD: ±15.31)
years, and 59% were female. The infliximab group was
younger and included a greater proportion of males than
the other two groups (Table 1).
To ensure the accuracy of the calculation of IRD-
related costs, some claims were defined as IRD-related
only if the related service was provided by a rheumatolo-
gist. Therefore, IRD-related costs were calculated only
for those patients who were treated by a rheumatologist.
347 of the 555 patients were treated at least once by a
rheumatologist during the year after the index event.
The mean age of these patients was 51 (±16.16) years,
and 63% were female. 153 of these patients were treated
with etanercept, 150 with adalimumab, and 44 with
infliximab.Figure 1 Study population.Annual costs of treatment
Costs during the 12 months after the index event were
20,555CHF in the etanercept group, 24,152CHF in the
adalimumab group, and 27,614CHF in the infliximab
group (Table 2). Costs in the SC group (adalimumab and
etanercept) were significantly lower than those in the IV
group (infliximab) (p < 0.001). Medication costs were by
far the most important cost driver. These were
17,751CHF in the etanercept group, 21,315CHF in the
adalimumab group, and 22,666CHF in the infliximab
group.
Specific IRD-related costs during the 12 months after
the index event were 16,824CHF (±8,589) in the etaner-
cept group, 20,532CHF (±9,228) in the adalimumab
group, and 23,952CHF (±11,833) in the infliximab
group. IRD-related costs were significantly lower in the
SC group than the IV group (p = 0.014). The most im-
portant cost drivers were TNF-inhibitor drug costs with
15,613CHF (±8,368) in the etanercept group, 19,166CHF
(±9,075) in the adalimumab group, and 21,313CHF
(±11,557) in the infliximab group.
Dosing patterns
For patients who continued on therapy with any of the
three TNF-inhibiting agents, the average annual inter-
application length of therapy (etanercept or adalimu-
mab) decreased during the two years following initiation
(Figure 2). For example, patients treated with etanercept
Table 2 Descriptive comparison of healthcare cost for the 12 months after the index event in CHF per patient
Mean (SD) 95%-CI Minimum Maximum
Etanercept (n = 233)
Outpatient care 1,113 (998) 984-1,241 0 5,775
Medications 17,751 (10,024) 16,457-19,045 1,058 102,156
Laboratory tests 585 (531) 517-654 0 4,114
Outpatient care in hospitals 453 (1,206) 297-609 0 12,382
Devices and aids 60 (220) 32-89 0 1,827
Other claims 593 (1,801) 360-825 0 19,749
Total direct cost (etanercept) 20,555 (10,740) 19,169-21,942 1,589 111,994
Adalimumab (n= 201)
Outpatient care 1,276 (965) 1,142-1,410 0 5,798
Medications 21,315 (9,008) 20,062-22,568 1,169 58,129
Laboratory tests 634 (521) 561-706 0 4,840
Outpatient care in hospitals 418 (891) 294-542 0 5,913
Devices and aids 90 (358) 40-140 0 4,004
Other claims 419 (810) 306-531 0 7,241
Total direct cost (adalimumab) 24,152 (9,403) 22,844-25,460 1,994 61,613
Infliximab (n = 121)
Outpatient care 1,087 (1,243) 863-1,310 0 6,358
Medications 22,666 (10,625) 20,754-24,579 4,247 68,590
Laboratory tests 1,024 (751) 889-1,159 0 4,176
Outpatient care in hospitals 2,363 (2,817) 1,856-2,871 0 23,271
Devices and aids 151 (258) 104-197 0 1,722
Other claims 323 (703) 196-449 0 4,304
Total direct cost (infliximab) 27,614 (11,860) 25,479-29,748 5,733 72,233
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stance for an average of 263 days with subsequent
declines over years 2 (n = 69, 242 days) and 3 (n = 37,
216 days). In contrast, the average annual treatment days
in the infliximab group increased from 286 days (n = 36)
in year 1 to 423 days (n = 6) in year 3.Figure 2 Averaged annual treatment over three years.The discontinuation rates during the first year after
the index event were 41.3% in the adalimumab group,
46.8% in the etanercept group, and 51.2% in the inflixi-
mab group. There was no significant difference between
the SC and IV groups (p = 0.172). The dosage increase
rate was 13.0% in the adalimumab group, 13.3% in the
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year after index event. There was no significant differ-
ence between the SC group and IV group (p = 0.832).
Daily costs of treatment
Patients stop taking these kinds of therapies for different
reasons. Lack of efficacy and occurrence of adverse
events range among the most important of the potential
reasons. The cost per patient for these therapies only for
the time period that patients are under active treatment
with one of these products is under current discussion.
This might explain the need for additional resources dur-
ing that time and gives a view without the “confounder”
of patients stopping treatment. There were no differences
in daily treatment costs between the SC therapies (i.e.,
etanercept and adalimumab). However, significant differ-
ences in treatment costs were observed between the SC
group and IV group (p < 0.001) (Table 3).
Discussion
A nationwide cost analysis of the outpatient anti-TNF
treatment of patients with the most prevalent IRDs in
Switzerland was performed using data from a largeTable 3 Descriptive comparison of mean daily treatment cost
after the index event in CHF
Mean (SD)
Etanercept (n = 233)
Outpatient care 4 (11)
Medications 83 (20)
Laboratory tests 2 (2)
Ambulatory care in hospitals 1 (3)
Devices and aids 0 (1)
Other claims 2 (7)
Total daily cost (etanercept) 92 (26)
Adalimumab (n= 201)
Outpatient care 4 (4)
Medications 84 (12)
Laboratory tests 2 (2)
Ambulatory care in hospitals 1 (3)
Devices and aids 0 (1)
Other claims 1 (3)
Total daily cost (adalimumab) 93 (14)
Infliximab (n = 121)
Outpatient care 4 (5)
Medications 118 (84)
Laboratory tests 3 (3)
Ambulatory care in hospitals 9 (9)
Devices and aids 1 (1)
Other claims 1 (2)
Total daily cost (infliximab) 135 (88)health insurer. A key strength of this study is that results
were based on real incurred costs data which represents
the daily life treatment setting. This approach is useful
for identifying health care costs from a health insurer
perspective.
There were marked differences in the descriptive com-
parison of costs among the etanercept, adalimumab, and
infliximab groups. Etanercept had the lowest and inflixi-
mab the highest all-cause costs during the year following
the index event. The relative magnitudes of these costs
were consistent with the calculated IRD-related costs.
Etanercept and adalimumab had similar daily costs of
treatment, while infliximab daily costs of treatment were
higher than both of the SC treatments. Earlier US-based
studies involving only RA patients reported similar find-
ings [5,6,14]. Studies conducted in institutional settings
have also reported infliximab to be costly relative to
other TNF inhibitors. For instance, a study using data
collected in 2005 from RA patients treated at Spanish
hospitals found that patients treated with etanercept had
lower health care costs than those treated with inflixi-
mab [9]. Dissimilar from earlier investigation, we esti-
mated costs for patients with any of several IRDs ands per patient for active treatment during the 12 months
95%-CI Minimum Maximum
3-6 0 164
80-86 62 301
2-2 0 18
1-1 0 18
0-0 0 5
1-3 0 95
89-96 69 328
4-5 0 22
82-86 65 159
2-2 0 21
1-2 0 17
0-0 0 11
1-2 0 29
91-95 68 169
3-4 0 25
103-133 36 823
3-4 0 17
7-10 0 65
0-1 0 4
0-1 0 12
119-151 63 878
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2008). Thus, our findings suggest that cost differences
between infliximab and the other TNF-inhibitors are a
persistent phenomenon and continue to be relevant in
the Swiss outpatient setting.
Dosage increases in clinical practice may have signifi-
cant cost implications for patients and payers, given the
linear relationship between dosage and costs [5]. A re-
cently published RA treatment algorithm advocates
shortening the dosing interval of adalimumab or increas-
ing the dose or shortening the dosing interval of inflixi-
mab in patients with an inadequate response prior to
switching to another TNF inhibitor [15]. Therefore, it is
important to understand the dosing regimens used for
TNF inhibitors in clinical practice. Dosage increase rates
were moderate in all three treatment groups in the
current study. However, when assessing dosing patterns
over three years, an increase of the average annual treat-
ment length was observed for infliximab in years 2 and
3 after the index event. In contrast, the number of treat-
ment days decreased in subsequent years for etanercept
and adalimumab. Upward dosage adjustment of inflixi-
mab in patients with RA has been associated with
increases of 30–50% in medication costs in recent stud-
ies [6,7]. For instance, Harrison et al. reported that
among naive and continuing patients, dose increases
from the first to the last prescription were more likely to
occur for infliximab (26% and 24%, respectively) then
adalimumab (10% and 9%, respectively) or etanercept
(1% and 3%, respectively) [5]. In our study, upward dose
adjustments for RA and the higher approved doses for
AS and PsA (i.e., 5 mg/kg vs. 3 mg/kg for RA) could
have contributed to higher medication costs for inflixi-
mab. Higher costs for outpatient care in hospitals, pre-
sumably for IV administration charges, may also have
influenced the observed infliximab costs.
The current study has several limitations. The observed
differences in costs may have been due to differences in the
proportions of RA, AS, and PsA patients in each treatment
group as well as differences in disease severity and activity
among the investigated IRDs. This is a limitation of retro-
spective claims data analyses in Switzerland where clinical
data are not available. ICD codes are not recorded in Swiss
claims data. This prevented us from differentiating among
patients with RA, AS, or PsA. To address this problem,
IRD-patients were identified from visits to rheumatologists,
and patients with a visit to a gastroenterologist or derma-
tologist were excluded (since Crohn´s disease or psoriasis
could have been the indication for the visit). The infliximab
group included significantly greater proportions of males
and younger patients than the other treatment groups. This
suggests that the infliximab group may have included a
higher proportion of AS patients, which could have magni-
fied between-group cost differences due to the dosing usedfor infliximab in AS patients. Patients who died during the
observation period were excluded due to the fact that only
patients for whom data were available for at least a full year
after the index event were included in the analysis. How-
ever, there is no reason to expect that cases were dispropor-
tionately distributed among the three study cohorts as
there is no evidence to support that there are different mor-
tality rates as a follow-up from therapy between the three
TNF inhibitors. Patients who switched therapy to another
TNF inhibitor within the follow-up period were not
included in the analysis. This group could contain several
patients who did not respond or did not tolerate the index
TNF inhibitor.
A further limitation with respect to the interpretation
of the results comes from the fact that incident as well as
prevalent cases are included in the analyses. It was not
possible to separate these two types of patients as the
data set was limited. Nevertheless, this only relates to the
absolute figures of the data presented as there is no rea-
son to hypothesize that there are relative differences be-
tween the different groups regarding this point. Finally,
the dosing calculations were based on filed claims paid
by the health insurer. Thus, the results may not reflect
the actual amount of infliximab administrated to the pa-
tient and may over- or underestimate the dosage for any
infusion. For example, a patient increasing from 1.2 to
1.8 vials would have appeared to have a stable dose of 2
vials if the interval between infusions remained the same,
whereas a patient increasing from 1.6 to 2.2 vials would
have been considered to move from 2 to 3 vials.
In summary, the results of this study provide insights
into the costs of IRD patients treated with TNF inhibitors
in Switzerland and are the first real-world cost estimates
for the entire spectrum of rheumatic diseases for which
TNF inhibitors are approved to treat. Our findings reflect
the actual medical use of TNF inhibitors without the lim-
itations of clinical trials and allow for a head to head
comparison although the inherent limitations of retro-
spective claims data analysis does not allow causal con-
clusion. Given the availability of several TNF inhibitors
with comparable efficacies [16,17] but different costs, the
findings of this study can assist payers in understanding
the financial burden of the treating IRDs with anti-TNF
agents and making meaningful cost comparisons. For
generalization, further studies, which combine costs of
TNF inhibitors with patients clinical characteristics (e.g.,
disease duration, pain severity, disease activity), which
may affect both drug choice and treatment outcome, are
certainly needed.
Conclusions
This claims data study demonstrates marked differences
in costs between subcutaneous and intravenous therap-
ies for patients with inflammatory rheumatic diseases.
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hibitor treatment, costs for the infliximab group were
highest during the year after the index event. Dosage in-
crease rates were moderate in all of the treatment
groups. No significant differences could be observed for
dosage increases and discontinuation rates.
Competing interests
The authors have declared no conflicts of interest.
Authors’ contributions
JZ was responsible for the conception and design of the study, performed
the statistical data analysis and drafted the manuscript. TM was involved in
the conception and design of the study, reviewed the manuscript and
revised it critically for important intellectual content. RM helped to draft the
manuscript and revised it critically for important intellectual content. JvK
helped to draft the manuscript and revised it critically for important
intellectual content. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Prof. Dr. med. Henning Zeidler, Emeritus, former Director
of the Division of Rheumatology, Medical School Hannover, for helpful
scientific advice and review of the manuscript.
Grant Supporter:
This work was supported by an unrestricted educational grant from Helsana
Versicherungen AG.
Author details
1Center for Health Economics Research Hannover (CHERH), Leibniz University
Hannover, Königsworther Platz 1, D-30167 Hannover, Germany. 2herescon
gmbh, Hannover, Germany. 3Department Internal Medicine, Division of
Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Received: 10 August 2012 Accepted: 18 September 2012
Published: 28 September 2012
References
1. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala
C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L,
Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-
Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van
Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop
KL, Wong J, Zink A, van der Heijde D: EULAR recommendations for the
management of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs. Ann Rheum Dis 2010,
69(6):964–975.
2. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der
Heijde D: International ASAS consensus statement for the use of anti-
tumour necrosis factor agents in patients with ankylosing spondylitis.
Ann Rheum Dis 2003, 62(9):817–824.
3. Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas
R, Landewé R, Rudwaleit M, Braun J: 2010 Update of the international
ASAS recommendations for the use of anti-TNF agents in patients with
axial spondyloarthritis. Ann Rheum Dis 2011, 70(6):905–908.
4. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH,
de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P,
Qureshi AA, Soriano ER, Taylor WJ: Treatment recommendations for
psoriatic arthritis. Ann Rheum Dis 2009, 68(9):1387–1394.
5. Harrison DJ, Huang X, Globe D: Dosing patterns and costs of tumor
necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst
Pharm 2010, 67(15):1281–1287.
6. Ollendorf DA, Klingman D, Hazard E, Ray S: Differences in annual
medication costs and rates of dosage increase between tumor necrosis
factor-antagonist therapies for rheumatoid arthritis in a managed care
population. Clin Ther 2009, 31(4):825–835.
7. Ollendorf DA, Massarotti E, Birbara C, Burgess SM: Frequency, predictors,
and economic impact of upward dose adjustment of infliximab in
managed care patients with rheumatoid arthritis. J Manag Care Pharm
2005, 11(5):383–393.8. Gilbert TD, Smith D, Ollendorf DA: Patterns of use, dosing, and economic
impact of biologic agent use in patients with rheumatoid arthritis: a
retrospective cohort study. BMC Musculoskelet Disord 2004, 5(1):36.
9. Rubio-Terrés C, Ordovás Baines JP, Pla Poblador R, Martínez Nieto C,
Sánchez Garre MJ, Rosado Souvirón MA, Sierra Muñoz A, Sánchez Mateo M,
Grupo de Investigadores del Estudio PRAXIS: Use and cost of biological
disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm
Hosp 2007, 31(2):78–92. in Spanish.
10. Bullano MF, McNeeley BJ, Yu YF, Quimbo R, Burawski LP, Yu EB:
Comparison of costs associated with the use of etanercept, Infliximab
and adalimumab for the treatment of rheumatoid arthritis. Manag Care
Interface 2006, 19(9):47–53.
11. Ruof J, Hülsemann JL, Mittendorf T, Handelmann S, von der Schulenburg
JM, Zeidler H, Merkesdal S: Costs of rheumatoid arthritis in Germany: a
micro-costing approach based on healthcare payer´s data sources. Ann
Rheum Dis 2003, 62(6):544–549.
12. Merkesdal S, Ruof J, Mittendorf T, Mau W, Zeidler H: Health economics
research in the area of chronic polyarthritis. Z Rheumatol 2002,
61(1):21–29. in German.
13. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M: Retrospective claims data
analysis of dosage adjustment patterns of TNF antagonists among
patients with rheumatoid arthritis. Curr Med Res Opin 2008,
24(8):2229–2240.
14. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M: Cost of care for patients with
rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Curr Med Res Opin 2007, 23(8):1749–1759.
15. Lutt JR, Deodhar A: Rheumatoid arthritis: strategies in the management
of patients showing an inadequate response to TNF alpha antagonists.
Drugs 2008, 68(5):591–606.
16. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R,
Lopez-Olivo MA, Ghogomu ET, Tugwell P: Biologics for rheumatoid
arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev
2009, 7(4):CD007848.
17. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-
Olivo MA, Ghogomu ET, Tugwell P: A network meta-analysis of randomize
controlled trials of biologics for rheumatoid arthritis: a Cochrane
overview. CMAJ 2009, 181(11):787–796.
doi:10.1186/2191-1991-2-20
Cite this article as: Zeidler et al.: Biologic TNF inhibiting agents for
treatment of inflammatory rheumatic diseases: dosing patterns and
related costs in Switzerland from a payers perspective. Health Economics
Review 2012 2:20.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
